Pricing Log in Create free account

ACADIA Pharmaceuticals Inc. (ACAD) vs Relay Therapeutics, Inc. (RLAY)

ACADIA Pharmaceuticals Inc. and Relay Therapeutics, Inc. are both Biotechnology companies. Relay Therapeutics, Inc. is the larger, with a market value of $3.8B against $3.4B — 1.1× the size. Relay Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ACADIA Pharmaceuticals Inc. trades at 8.5×. ACADIA Pharmaceuticals Inc. grew revenue faster over the last twelve months: 11.8% against −74.3%. ACADIA Pharmaceuticals Inc. has the higher net margin (33.4% vs −2,594.2%) and the higher return on invested capital (15.4% vs 0.00%). Across the 17 metrics below, ACADIA Pharmaceuticals Inc. leads on 15 and Relay Therapeutics, Inc. on 2.

Valuation

Metric ACAD RLAY Biotechnology median
P/E 8.50 n/m 8.50
P/S 2.88 299.51 9.71
P/B 2.51 3.71 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 24.19 n/m 0.64
EV/Sales 2.04 216.89 9.21
Earnings yield 11.77% (9.64%) (33.15%)
Free cash flow yield (1.59%) (6.44%) (25.50%)

Profitability

Metric ACAD RLAY Biotechnology median
Gross margin 91.13% 100.00% 65.16%
Operating margin 7.59% (2,815.49%) 0.00%
Net margin 33.42% (2,594.20%) 0.00%
Free cash flow margin 12.79% (1,924.59%) 0.00%
Return on equity 35.74% (36.77%) (56.36%)
Return on assets 25.64% (33.72%) (48.04%)
Return on invested capital 15.42% 0.00% 0.00%

Growth

Metric ACAD RLAY Biotechnology median
Revenue growth (TTM) 11.75% (74.29%) 6.02%
EPS growth (last fiscal year) 69.12% 31.78% 30.26%
Revenue growth, 5-year CAGR 19.39% (28.58%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACAD RLAY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.39 18.27 4.72
Net debt to EBITDA (7.37) 1.84 0.96

Dividend

Metric ACAD RLAY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACAD RLAY Biotechnology median
Market cap 3.40b 3.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack